Literature DB >> 12919710

Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis.

P Ravn1, Desmond E Thompson, Philip D Ross, C Christiansen.   

Abstract

Short-term changes in biochemical markers of bone turnover (bone markers) have been suggested as predictors of long-term response in bone mass during antiresorptive treatment. In the Danish cohort (n = 306) of the Early Postmenopausal Intervention Cohort (EPIC) Study (n = 1609) of oral alendronate (ALN) for prevention of postmenopausal osteoporosis, bone markers (urine C-telopeptides of type I collagen (uCTX), urine N-telopeptide cross-links of type I collagen (uNTX), serum total osteocalcin measured by ELISA [total OC (ELISA)], and serum total osteocalcin measured by RIA [total OC (RIA)]) were measured at 6-month intervals. The correlation between 6-month change in uCTX and 4-year change in spine and hip bone mineral density (BMD) was r = -0.41 and r = -0.42, respectively (P < 0.001). The corresponding values for the other bone markers were r = -0.53 and r = -0.42 (uNTX), r = -0.46 and r = -0.47 [total OC (ELISA)], and r = -0.43 and r = -0.41 [total OC (RIA)], all P < 0.001. ROC curves were used to analyse the ability of the bone markers to predict a change in spine BMD greater than 0%. The best performance [defined as the maximum value of (sensitivity plus specificity)] was found at the cut-off values of a -29% change from baseline in uCTX, a -45% change from baseline in uNTX, a -13% change from baseline in total OC (ELISA), and a -15% change from baseline in total OC (RIA). At these values the corresponding sensitivity was 66% (uCTX), 76% (uNTX), 70% [total OC (ELISA)], and 83% [total OC (RIA)]. The specificity was 80% (uCTX), 75% (uNTX), 71% [total OC (ELISA)], and 55% [total OC (RIA)]. The positive predictive value (PPV) was 82% (uCTX), 80% (uNTX), 77% [total OC (ELISA)], and 71% [total OC (RIA)]. The negative predictive value (NPV) was 64% (uCTX), 70% (uNTX), 64% [total OC (ELISA)], and 71% [total OC (RIA)]. In conclusion, the bone markers predicted a change in spine BMD greater than 0% with a high PPV and specificity. There was a trend toward better performance in this respect for the bone resorption markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919710     DOI: 10.1016/s8756-3282(03)00168-6

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

1.  Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.

Authors:  J Natsag; M A Kendall; D E Sellmeyer; G A McComsey; T T Brown
Journal:  HIV Med       Date:  2015-07-16       Impact factor: 3.180

2.  Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial.

Authors:  Kerri M Winters-Stone; Jessica Dobek; Lillian Nail; Jill A Bennett; Michael C Leo; Arpana Naik; Anna Schwartz
Journal:  Breast Cancer Res Treat       Date:  2011-03-19       Impact factor: 4.872

Review 3.  Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?

Authors:  Morten A Karsdal; Per Qvist; Claus Christiansen; László B Tankó
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Nutritional approach for inhibiting bone resorption in institutionalized elderly women with vitamin D insufficiency and high prevalence of fracture.

Authors:  J-P Bonjour; V Benoit; O Pourchaire; B Rousseau; J-C Souberbielle
Journal:  J Nutr Health Aging       Date:  2011-05       Impact factor: 4.075

5.  Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.

Authors:  I Byrjalsen; D J Leeming; P Qvist; C Christiansen; M A Karsdal
Journal:  Osteoporos Int       Date:  2007-09-11       Impact factor: 4.507

Review 6.  Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Authors:  Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

7.  The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality.

Authors:  M A Karsdal; I Byrjalsen; D J Leeming; P D Delmas; C Christiansen
Journal:  Osteoporos Int       Date:  2008-04-03       Impact factor: 5.071

8.  Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

Authors:  Er-Yuan Liao; Zhen-Lin Zhang; Wei-Bo Xia; Hua Lin; Qun Cheng; Li Wang; Yong-Qiang Hao; De-Cai Chen; Hai Tang; Yong-De Peng; Li You; Liang He; Zhao-Heng Hu; Chun-Li Song; Fang Wei; Jue Wang; Lei Zhang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.